Review Integrates Functional and Aesthetic BTX-A Treatment for Facial Paralysis
Key Takeaways
- Facial paralysis can involve facial asymmetry, synkinesis, painful muscle contractions, hemifacial spasms, and autonomic symptoms.
- A new narrative review found that botulinum toxin A (BTX-A) may address both aesthetic asymmetry and functional or therapeutic manifestations of facial paralysis.
- The authors proposed an evidence-based neuroaesthetic framework that utilized functional, therapeutic, and aesthetic treatment goals when using BTX-A.
Botulinum toxin A (BTX-A) may offer dermatologists a way to address the functional, therapeutic, and aesthetic manifestations of facial paralysis within a single treatment framework, a recent review suggested.d
BTX-A Targets Multiple Sequelae of Facial Paralysis
The authors conducted a narrative review of PubMed-indexed literature examining aesthetic and therapeutic applications of BTX-A in facial paralysis and focused on 3 domains: facial asymmetry, functional impairment, and neuromuscular dysregulation.
According to the reviewers, the available literature supports BTX-A for reducing hyperkinesis and improving facial symmetry. Therapeutic benefits were also reported for synkinesis, painful contractions, hemifacial spasms, and gustatory lacrimation. The proposed framework, published in the Journal of Drugs in Dermatology, integrates treatment of these symptoms with aesthetic correction rather than considering each indication separately. The report did not provide pooled effect estimates or comparative efficacy data.
“This review introduces a neuroaesthetic framework that unifies aesthetic, functional, and therapeutic applications of BTX-A in facial paralysis and emphasizes its multi-systemic complexity,” the authors concluded. “With appropriate knowledge and understanding of facial nerve dysfunction, dermatologists and clinicians experienced with neuromodulators are well positioned to deliver comprehensive function-guided treatments across the spectrum of facial paralysis-related sequelae.”
Source
Scemla R, Gladstone H. Journal of Drugs in Dermatology. 2026;25(9):800.